SCHEMBL669034

SCHEMBL669034

CCOC(=O)C1(N)CC1C1CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM1 Q13255 1/20 0.35
GAA P10253 2/20 0.34
ALOX15 P16050 1/20 0.34
MGAM O43451 1/20 0.34
SI P14410 1/20 0.34
MGAM2 Q2M2H8 1/20 0.34
EPHX2 P34913 1/20 0.34
POLB P06746 1/20 0.33
MAPK1 P28482 1/20 0.33
ALDH1A1 P00352 3/20 0.32
CYP1A2 P05177 1/20 0.32
TRPA1 O75762 1/20 0.32
SMYD3 Q9H7B4 1/20 0.32
LMNA P02545 2/20 0.32
ATM Q13315 1/20 0.32
HSD17B10 Q99714 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10093291 1.00 GRM1 (0.35) GRM1GAAALOX15MGAMSI
SCHEMBL27772736 0.93 KMT2A (0.36) GAAALOX15MGAMSIMGAM2
SCHEMBL3375726 0.79 GRM1 (0.38) GRM1
SCHEMBL32674074 0.79 GRM1 (0.38) GRM1
SCHEMBL12868635 0.77 ALDH1A1 (0.41) GAAALOX15MGAMSIMGAM2
SCHEMBL26521044 0.77 ALDH1A1 (0.41) GAAALOX15MGAMSIMGAM2
SCHEMBL17479967 0.77 ALDH1A1 (0.41) GAAALOX15MGAMSIMGAM2
SCHEMBL32674026 0.77 ALDH1A1 (0.41) GAAALOX15MGAMSIMGAM2
SCHEMBL26529108 0.77 ALDH1A1 (0.41) GAAALOX15MGAMSIMGAM2
SCHEMBL27667349 0.77 KMT2A (0.37) POLBMAPK1ALDH1A1CYP1A2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023044171-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2023-03-23 WO disclosed
EP-2606038-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C Bristol-Myers Squibb Company (US) 2013-06-26 EP disclosed
WO-2012024373-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-23 WO disclosed
EP-2300490-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2011-03-30 EP disclosed
WO-2009146347-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-03 WO disclosed
EP-1505945-A4 SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2006-11-22 EP disclosed
EP-1505945-A2 SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Pharma Company (US) 2005-02-16 EP disclosed
WO-2004043339-A2 SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-05-27 WO disclosed